ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
CD8
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- Article
- Oligonucleotide G3T19 downregulates CD44 succinylation and inhibits astrocyte-induced glioma immune escape.Cell communication and signaling : CCS · 2026Article
- Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.Nature communications · 2026Article
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- Immunologic specificity in glioblastoma: Antigen discovery and translational implications.Neuro-oncology advances · 2025Review
- Integrative analysis reveals key molecular mechanisms and prognostic model for Ethylnitrosourea-induced gliomagenesis.BMC pharmacology & toxicology · 2025Article
- Review
- LINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis.Journal of cellular and molecular medicine · 2024Article
- MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacy.bioRxiv : the preprint server for biology · 2024Article
- Clonal Extinction Drives Tumorigenesis.Cancers · 2023Article
- Article
- Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.Acta neuropathologica communications · 2023Review
- Construction and validation of a novel prognostic signature for cutaneous melanoma based on ferroptosis-related genes.Heliyon · 2023Article
- Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.Medical oncology (Northwood, London, England) · 2023Article
- Novel strategies for cancer immunotherapy: counter-immunoediting therapy.Journal of hematology & oncology · 2023Review
- Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.The Journal of clinical investigation · 2023Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.Journal of hematology & oncology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Joshua R Kane *Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Junfei Zhao *Department of Systems Biology, Columbia University, New York City, New York.
Takashi Tsujiuchi *Department of Neurosurgery, Columbia University, New York City, New York.
Brice LaffleurDepartment of Microbiology and Immunology, Columbia University, New York City, New York.ORCID 0000-0003-2904-9345
Víctor A ArrietaDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Aayushi MahajanDepartment of Neurosurgery, Columbia University, New York City, New York.
Ganesh RaoDepartment of Neurological Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Angeliki MelaDepartment of Pathology and Cell Biology, Columbia University, New York City, New York.
Crismita DmelloDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Li ChenDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Daniel Y ZhangDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0001-9962-9295
Edgar González-BuendiaDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Catalina Lee-ChangDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ting XiaoDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Gerson RothschildDepartment of Microbiology and Immunology, Columbia University, New York City, New York.
Uttiya BasuDepartment of Microbiology and Immunology, Columbia University, New York City, New York.
Craig HorbinskiDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Maciej S LesniakDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Amy B HeimbergerDepartment of Neurological Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Raul RabadanDepartment of Systems Biology, Columbia University, New York City, New York.
Peter CanollDepartment of Pathology and Cell Biology, Columbia University, New York City, New York.
Adam M SonabendDepartment of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. adam.sonabend@nm.org.ORCID 0000-0002-8347-1945
Northwestern University · USCity University of New York · USColumbia University Irving Medical Center · USThe University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Pouya Jamshidi · 2018 to 2026
$21.4MRole of ncRNA Surveillance Complex "RNA Exosome" in Class Switch Recombination and Somatic HypermutationR01AI099195 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Uttiya Basu · 2012 to 2026
$9.8MTherapeutic Targeting of Malignant Glioma Stem CellsR35CA197725 · NCI · UNIVERSITY OF CHICAGO · PI LESNIAK, MACIEJ S · 2015 to 2021
$6.2MLong noncoding RNA expressing genomic element that control antibody diversification and chromosomal integrity in B cellsR01AI134988 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Uttiya Basu · 2018 to 2026
$4.7MTOP2A effects on transcription in gliomas: implications for personalized therapyDP5OD021356 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SONABEND, ADAM M · 2015 to 2019
$2.0MArginine Metabolism Regulates Myeloid Immune Suppression in GlioblastomaR01NS115955 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LESNIAK, MACIEJ S, MISKA, JASON · 2020 to 2024
$1.9MMAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapyR01NS110703 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SONABEND, ADAM M · 2020 to 2024
$1.9MMODELING MALIGNANT PROGRESSION IN GLIOMAR01NS094615 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RAO, GANESH · 2016 to 2020
$1.8MTissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and MalignancyR01NS102669 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL · 2017 to 2021
$1.7MNCATS NIH HHS UL1 TR001422NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA221747NCI NIH HHS R35 CA197725NIAID NIH HHS R01 AI099195NIAID NIH HHS R01 AI134988NIH HHS DP5 OD021356NINDS NIH HHS R01 NS094615NINDS NIH HHS R01 NS102669NINDS NIH HHS R01 NS110703NINDS NIH HHS R01 NS115955NINDS NIH HHS R01 NS117104
Abstract
purposeCancer immunoediting shapes tumor progression by the selection of tumor cell variants that can evade immune recognition. Given the immune evasion and intratumor heterogeneity characteristic of gliomas, we hypothesized that CD8 EXPERIMENTAL
designWe developed retrovirus-induced PDGF
resultsUpon transplantation, gliomas that developed in the absence of CD8
conclusionsOur studies indicate that, in these tumor models, CD8
Indexed as
AnimalsAntigens, NeoplasmBrain NeoplasmsCD8-Positive T-LymphocytesDisease Models, AnimalGliomaHumansImmune EvasionMacrophagesMiceMicrogliaT-LymphocytesAntigens, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.